NCT06380907Phase 2Terminated

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Study sponsor: Zai Lab (Hong Kong), Ltd.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-12-16Actual

Enrollment · participants65Actual

Source updated2026-08-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-10 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~250 participants (planned)~~

+ After

65 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~28 Feb 2026~~

+ After

16 Dec 2025

Recruitment status changed

− Before

~~Recruiting~~

+ After

Terminated

Check registry source

Study details

Conditions studied

Plaque Psoriasis

Treatments or interventions studied

ZL-1102 1% w/w gel BID for 16 weeksDrug
ZL-1102 3% w/w gel BID for 16 weeksDrug
ZL-1102 3% w/w gel QD for 16 weeksDrug
Placebo ZL-1102 0% w/w gel BID for 16 weeksDrug
Placebo ZL-1102 0% w/w gel QD for 16 weeksDrug

Primary outcomes · main study measures

measure: Efficacy of different doses of ZL-1102 compared to Vehicle at Week 16.; description: The proportion of patients achieving mPASI 75 (at least a 75% reduction in mPASI score from baseline) at Week 16.; timeFrame: 16 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history